Browse bulletin items by A-Z

Published: 26 August, 2022


Today is Daffodil Day

Today marks the 32nd annual Daffodil Day. Funds from the annual appeal contribute towards cancer care for patients and their Whānau through the Cancer Society, education and awareness programmes and cancer research efforts.

Each day in New Zealand, 71 people are diagnosed with cancer. This number has been steadily increasing over the years and there are significant disparities in cancer detection, treatment and outcomes for Māori in particular. Te Aho o Te Kahu, the Cancer Control Agency, was established by the Government in response to this need. Its role is to lead and unite efforts by all service providers, organisations and people involved in cancer care to deliver better cancer outcomes for New Zealand.

The bpacnz website has a dedicated section for resources supporting cancer care in New Zealand. Click here to view updates on bowel, lung and prostate cancer, melanoma and cancer cachexia. Later this year we will be publishing a series on early detection and follow-up of gynaecological cancers, supported by Te Aho o Te Kahu.

In case you missed it: latest articles

We regularly add new content to our website - browse articles under the “latest tab” or search for a topic you are interested in. Here are some of our most recently published resources:

Monkeypox update

When we first reported about monkeypox in Bulletin 51, there were no cases in New Zealand; there are now four confirmed cases. Guidance for clinicians, the case definition, testing criteria and infection prevention and control measures for monkeypox have now been published by Manatū Hauora, The Ministry of Health. N.B. The World Health Organization is still consulting on the renaming of monkeypox disease and virus.

For further information, see the Monkey-pox – clinical update and Communicable Disease Control Manual

Flu vaccine uptake is increasing over time

This year’s influenza campaign is tracking to be one of the most successful in recent years in terms of vaccine uptake. More vaccines have been administered this year to date than in the previous two years.

Progress has been made since we last reported on vaccination rates in Bulletin 54, however, there are still many eligible people who have not yet received their funded influenza vaccination. Most recent data show that 70.3% of adults aged 65 years or over have received an influenza vaccination – this is approaching the national target of 75%. Vaccination rates remain lower in Māori (66.0%) and Pacific peoples (63.1%) but are, however, steadily increasing over time.

Māori and Pacific peoples aged 55 years or over are also eligible to receive a funded influenza vaccination this year. Currently, the vaccination rates for Māori aged 55 to 64 years is only 36.7% and 40.4% for Pacific peoples; this has also increased since we last reported, but ideally these rates would be much higher.

For further information, including regional data, see:

Access criteria announced for new COVID-19 treatment

Access criteria for a newly available pre-exposure prophylaxis for COVID-19, tixagevimab and cilgavimab (Evusheld), has been announced for people with severe immunocompromise at high risk of COVID-19 infection. Evusheld is available now in some hospitals throughout New Zealand and will be available in the community from mid-September, 2022. Access criteria can be viewed here.

Evusheld is administered as two injections of monoclonal antibodies that target different aspects of the spike protein of SARS-CoV-2. Protection is thought to last for at least six months; repeat dosing is currently not funded.

For further information on available COVID-19 treatments, see:

Intra-uterine device: check instructions

A possible stock shortage of intra-uterine device (IUD) Choice TT380 Short has been reported; existing stock is expected to be exhausted by mid-September. Other IUDs are not affected.

From 1 September, 2022, two additional IUDs* will be listed on the Community Schedule, however, these products have different dimensions and insertion methods than the Choice TT380 Short. It is essential that instructions are checked prior to the insertion of the new device.

*The replacement products to be listed are the same device (380 7 Med NSHA) except one has packaging in both French and English

For information on intra-uterine devices and other long-acting contraceptives, see:

The use of opioids and serotonin syndrome

Following international evidence of an interaction between opioids and serotonergic medicines causing serotonin syndrome, the Medicines Adverse Reactions Committee (MARC) was asked to review this risk. The findings have been released in the latest meeting minutes.

The Committee agreed that there was a risk of serotonin syndrome from taking an opioid with another serotonergic medicine and this risk differed between opioids; tramadol, pethidine and dextromethorphan are considered high risk and fentanyl and methadone are considered medium risk (although high risk at increased doses). Prescribers should be aware of this risk for patients concurrently taking opioids and serotonergic medicines, e.g. SSRIs or over-the-counter products such as St Johns Wort.

The full report, including MARC recommendations for medicine datasheet amendments can be read here

A reminder on the risk of DRESS with some medicines

As reported in the latest meeting of the Medicines Adverse Reactions Committee (MARC) in June, certain medicines must be initiated and titrated differently to reduce the risk of drug rash with eosinophilia and systemic symptoms (DRESS). This reminder comes following a CARM report of death with DRESS due to allopurinol.

DRESS is a rare, but potentially fatal condition, characterised by an erythematous, desquamating rash, fever, eosinophilia, leukocytosis, hepatitis and renal failure. Advise patients taking medicines that have an increased risk of DRESS (e.g. allopurinol, anticonvulsants and beta-lactam antibiotics) to seek medical advice if they develop a rash or pruritis.

For information on the risk of DRESS with allopurinol, see:

HIV action plan released

Manatū Hauora, The Ministry of Health, has released a draft ten-year HIV elimination plan with the vision being for New Zealand to be a place where HIV transmission is eliminated and all people living with HIV can live healthy lives free from stigma and discrimination.

HIV and AIDS is a global epidemic that has resulted in the deaths of 757 people in New Zealand. The Joint United Nations Programme on HIV and AIDS (UNAIDS) launched the 2021 Political Declaration on AIDS which sets targets to guide global efforts in the elimination of HIV transmission and AIDS as a public health threat. New Zealand is a signatory to this declaration.

Read the full report here

Paper of the Week: Should we be recommending vaping as an alternative to smoking?

Electronic cigarettes (e-cigarettes) or ‘vaping’ has increased in popularity in recent times, particularly among adolescents, and is now a common form of nicotine-replacement therapy for smoking cessation.

This week we share a discussion on e-cigarettes and vaping released by the GP notebook podcast. This podcast delves into why vaping has become so popular and what the benefit to smokers is, but most importantly raises the big question on whether we should be recommending vaping as an alternative to patients who smoke.

Listen to the full GP notebook podcast here (approx. 17 minutes)

N.B. For further listening, a podcast on youth vaping with Dr Colette Muir, Developmental Paediatrician, Starship Children’s Health, is available here from the Goodfellow Unit.

This Bulletin is supported by the South Link Education Trust

If you have any information you would like us to add to our next bulletin, please email:

ASK A COLLEAGUE: Are they receiving these bulletins? Sign up to our mailing list here

© This resource is the subject of copyright which is owned by bpacnz. You may access it, but you may not reproduce it or any part of it except in the limited situations described in the terms of use on our website.

Made with by the bpacnz team

Partner links